Abstract:Herein, we described the synthesis of some new phthalazine piperazine‐pyrazole conjugates(6a‐n) and their in vitro anticancer activity against four human cancer cell lines such as PC‐3, MCF‐7, DU‐145, and A‐549. The anticancer activity results reveals that the four compounds 6c, 6h, 6i, and 6n shown promising activity than the standard drug Erlotinib. Furthermore, the in silico studies of compounds 6c, 6h, 6i, and 6n supports the in vitro anticancer results. In addition, ADMET analyses were carried out on four potent compounds and results accordant with the in vitro anticancer and in vitro EGFR tyrosine kinase inhibition data. In this paper, we describe the synthesis of some new quinoxaline‐piperazine‐oxazole amide conjugates 6a‐n from 3‐chloroquinoxaline‐2‐carbonitrile using well‐known reaction sequences. The synthesized compounds were characterized by 1H NMR,13C NMR, and mass spectral analysis. The compounds were tested for their in vitro antiproliferative activity toward four different cancer cell lines such as PC‐3, MCF‐7, DU‐145, and A‐549 by MTT method. The compounds, 6c, 6h, 6i, and 6n were found to be more potent than the standard Erlotinib. In vitro tyrosine kinase EGFR inhibition studies using four potent compounds revealed that 6n has double inhibiting tendency with value IC50 of 0.22 μM and 6h with value of IC50 0.27 μM compared to reference compound. Molecular docking studies of active compounds, 6c, 6h, 6i, and 6n on EGFR receptor suggested that all the compounds have more binding energies than that of Erlotinib. Furthermore, the in silico pharmacokinetic profile was accomplished for the active compounds, 6c, 6h, 6i, and 6n using SWISS/ADME and pk CSM, whereas compounds, 6h, 6i, and 6c followed Lipinski rule, Veber rule, Egan rule and Muegge rule. The remaining compound 6n did not follow Lipinski rule, Ghose rule because one common violation, that is, because of high molecular weight (MW > 350).

A Novel Class of Cyclophosphamide Prodrug: Structure-Activity Relationships of Cyclophosphamide Piperaziniums

Novel Class of Cyclophosphamide Prodrug: Cyclophosphamide Spiropiperaziniums (Cpsp)

Design of New Benzo[h]chromene Derivatives: Antitumor Activities and Structure-Activity Relationships of the 2,3-Positions and Fused Rings at the 2,3-Positions

Synthesis and Structure-Activity Relationships of a Novel Class of Dithiocarbamic Acid Esters As Anticancer Agent.

Novel Class of Cyclophosphamide Prodrug: Cyclophosphamide Spiropiperaziniums (CPSP).

Synthesis and anticancer activity of novel C6-piperazine substituted purine steroid–nucleosides analogues

Synthesis of a novel class of cyclophosphamide bis-spiropiperazinium salts

Synthesis and anti-tumor activity of 1-［bi-(4-fluoroph enyl)-methyl］-4-substituted piperazines Synthesis and anti-tumor activity of 1-［bi-(4-fluoroph enyl)-methyl］-4-substituted piperazines

Structure-Activity Relationship Study of New Carbazole Sulfonamide Derivatives as Anticancer Agents with Dual-target Mechanism

Structure-activity Relationships of Novel Dithiocarbamates Containing Α,β-Unsaturated Ketone Fragment As Potent Anticancer Agents

Design, Synthesis, and Activity Evaluation of Novel Acyclic Nucleosides as Potential Anticancer Agents <i>In Vitro</i> and <i>In Vivo</i>

Design, Synthesis, and Activity Evaluation of Novel Acyclic Nucleosides as Potential Anticancer Agents In Vitro and In Vivo

Novel pyridine bearing pentose moiety-based anticancer agents: design, synthesis, radioiodination and bioassessments

Synthesis of novel piperazine-based bis(thiazole)(1,3,4-thiadiazole) hybrids as anti-cancer agents through caspase-dependent apoptosis

Design and Synthesis of Carbothioamide/Carboxamide-Based Pyrazoline Analogs as Potential Anticancer Agents: Apoptosis, Molecular Docking, ADME Assay, and DNA Binding Studies.

A Comparative In Vitro Anticancer Evaluation and In Silico Study of New 1‐(1,3‐Oxazol‐5‐yl)piperidine‐4‐sulfonylamides

Synthesis, crystal structure, anti-bone cancer activity and molecular docking investigations of the heterocyclic compound 1-((2S,3S)-2-(benzyloxy)pentan-3-yl)-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl) phenyl)-1H-1,2,4-triazol-5(4H)-one

Synthesis and Biological Evaluation of Novel C6-cyclo Secondary Amine Substituted Purine Steroid-Nucleosides Analogues.

Ultrasonic-assisted synthesis and antitumor evaluation of novel variant heterocyclic compounds based on piperidine ring

New quinoxaline‐piperazine‐oxazole conjugates: Synthesis, in vitro anticancer, in silico ADMET, and molecular docking studies

Synthesis Of Diaryl Ether Substituted Piperazine Derivatives And Their Cytotoxic Activities